查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087756

組織診斷市場：2026-2032年全球市場預測（依產品類型、技術、工作流程階段、應用及最終使用者分類）

Tissue Diagnostics Market by Product Type, Technology, Workflow Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，組織診斷市場將成長至 132 億美元，複合年成長率為 8.22%。

主要市場統計數據
基準年 2025 75.9億美元
預計年份：2026年 81.9億美元
預測年份 2032 132億美元
複合年成長率 (%) 8.22%

組織學診斷是癌症檢測、腫瘤分型、預後評估和治療方案選擇的臨床基礎。隨著全球癌症發生率的上升，檢查室需要在保持診斷準確性的同時，提供更快、更可重複的病理學結果。根據國際癌症研究機構（IARC）估計，2022年全球新增癌症病例約2000萬例，癌症相關死亡病例約970萬例，凸顯了組織病理學、免疫組織化學、原位雜合反應和分子組織學在現代癌症診療中的關鍵作用。

精準醫療、伴隨診斷、檢查室自動化、數位病理學和人工智慧的整合正在重塑組織診斷領域。醫療系統擴大利用組織來源的生物標記物，例如HER2、PD-L1、ER/PR、ALK、ROS1、BRAF、EGFR和錯配修復狀態，來指南標靶治療和免疫療法的決策。因此，組織診斷已成為診斷設備製造商、參考實驗室、醫院網路、癌症中心以及開發生物標記主導療法的製藥合作夥伴的策略重點。

組織診斷領域的變革性變化

組織診斷領域正從傳統的以顯微鏡為中心的工作流程轉向整合、數據豐富的診斷生態系統。全切片成像、自動化染色平台、數位病理網路和實驗室資訊系統的整合，正在提高報告速度、可追溯性和標準化程度，從而改善高通量病理操作。隨著負責人面臨日益複雜的病例、對特定專科複評需求的成長以及組織來源生物標記組合的廣泛應用，這種轉變尤為重要。

人工智慧對組織診斷的累積影響

人工智慧 (AI) 正日益成為組織學診斷的實用驅動力，它能夠支援影像分析、病例優先排序、品管、生物標記定量和工作流程最佳化。 AI 工具可以幫助病理學家識別感興趣的區域、測量染色強度並量化腫瘤浸潤淋巴細胞，從而提高易受觀察者間差異影響的任務的一致性。這些功能只有在經過不同資料集的檢驗並整合到符合監管規定的臨床工作流程中時，才能發揮其最大價值。

組織診斷領域的主要區域趨勢

北美憑藉其先進的腫瘤學基礎設施、伴隨診斷的高普及率、完善的臨床檢驗檢測保險報銷體係以及眾多獲得CLIA認證的檢查室，仍然是組織診斷領域的領先地區。美國尤其具有舉足輕重的地位，這得益於其龐大的癌症檢測量、完善的病理網路以及FDA對體外診斷和檢查室自建檢測（LDT）的持續支持。在加拿大，數位病理學的應用正透過省級醫療保健系統、大學醫院和癌症治療網路不斷推進。

影響組織診斷需求的關鍵群體特定見解

歐盟在組織診斷領域發揮核心作用，體外診斷醫療設備法規 (IVDR) 的協調統一重塑了診斷設備製造商和實驗室的臨床證據、上市後監管、性能評估和品質要求。七國集團 (G7) 擁有成熟的腫瘤學體系、完善的保險報銷機制和高額的醫療費用支出，正引領著自動化染色、數位病理學、人工智慧影像分析和伴隨診斷等技術的先進應用。

組織診斷發展的關鍵國家概況

美國憑藉其先進的癌症中心、伴隨診斷的精細化應用、免疫組化技術的廣泛應用以及龐大的獨立實驗室和醫院附屬檢查室網路，引領著組織學診斷技術的發展。加拿大受益於其協調的癌症診療體系和省級檢查室網路，而墨西哥則透過發展私人醫療機構、參考檢查室和腫瘤科服務來擴大服務覆蓋範圍。巴西擁有龐大的檢測量以及對免疫組化和分子病理學日益成長的需求，是拉丁美洲最重要的組織學診斷中心。

為領導者提供的組織診斷實用建議

產業領導者應優先考慮經過臨床檢驗且與工作流程整合的組織診斷解決方案。這些解決方案能夠縮短檢測時間、提高可重複性，並支持基於生物標記的癌症治療。投資應重點關注自動化染色、標準化樣本製備、數位病理互通性、透明檢驗的人工智慧工具以及可與實驗室資訊系統和電子健康記錄整合的擴充性數據基礎設施。

組織診斷分析的調查方法

本執行摘要是基於對二手研究、監管趨勢以及資訊來源的分析，這些來源包括全球癌症統計數據、國家衛生機構、病理學專業協會、監管機構、同行評審文獻和公共資訊。研究方法著重於已證實的促進因素，例如癌症發生率、精準醫療的普及、診斷流程的現代化、對生物標記檢測的需求以及監管變化。

結論：組織學診斷在精準腫瘤學的應用

組織診斷正從一項簡單的檢查室工作轉變為精準腫瘤學的策略支柱。癌症發生率的上升、基於生物標記的療法的推廣以及對更快病理工作流程日益成長的需求，都提升了可靠的組織檢測在整個醫療保健系統中的重要性。數位病理學和人工智慧並非旨在取代病理學家，而是在完善的檢驗和管治的支持下，開發出能夠提高效率、一致性和可及性的工具。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：組織診斷市場：依產品類型分類

  • 裝置
    • 分析設備和掃描儀
    • 顯微鏡
  • 試劑和試劑盒
    • 酵素和緩衝液
    • 染色試劑
  • 服務
    • 合約研究
    • 客製化檢測開發

第8章：組織診斷市場：依技術分類

  • 流式細胞技術
    • 自動細胞計數裝置
    • 桌面式場地測量儀
  • 免疫組織化學
    • 顯色方法
    • 螢光法
  • 原位雜合反應
    • CISH
    • FISH
  • 微陣列和定序
    • DNA微陣列
    • 次世代定序

第9章：組織診斷市場：依工作流程階段分類

  • 預分析過程
  • 分析
  • 分析後

第10章：組織診斷市場：依應用領域分類

  • 細胞成像與分析
    • 數位影像分析
    • 螢光顯微鏡
  • 伴隨診斷
    • 標靶治療的選擇
    • 監測治療效果
  • 感染疾病
    • 細菌病原體的檢測
    • 病毒病原體的檢測
  • 腫瘤譜分析
    • 基因表現分析
    • 突變檢測

第11章：組織診斷市場：依最終使用者分類

  • 醫院/診斷檢查室
    • 大學醫院
    • 區域檢查室
  • 製藥公司
  • 研究機構
    • 政府研究機構
    • 私人研究

第12章：組織診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：組織診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：組織診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Abcam plc
  • Agilent Technologies, Inc.
  • Akoya Biosciences, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioGenex Laboratories, Inc.
  • bioMerieux SA
  • Cell Signaling Technology, Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • GE HealthCare Technologies Inc.
  • Histoline Laboratories Srl
  • Hologic, Inc.
  • Illumina, Inc.
  • Medite Medical GmbH
  • Merck KGaA
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd
  • Sakura Finetek Japan Co., Ltd.
  • Siemens Healthineers AG
  • SLEE medical GmbH
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-03142C0401D5

The Tissue Diagnostics Market is projected to grow by USD 13.20 billion at a CAGR of 8.22% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.59 billion
Estimated Year [2026] USD 8.19 billion
Forecast Year [2032] USD 13.20 billion
CAGR (%) 8.22%

Tissue diagnostics is the clinical foundation for cancer detection, tumor classification, prognostic assessment, and therapy selection. As global cancer incidence rises, laboratories are under pressure to deliver faster, more reproducible pathology results while preserving diagnostic accuracy. The International Agency for Research on Cancer reported an estimated 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, underscoring the essential role of histopathology, immunohistochemistry, in situ hybridization, and molecular tissue testing in modern oncology care.

The tissue diagnostics landscape is being shaped by the convergence of precision medicine, companion diagnostics, laboratory automation, digital pathology, and artificial intelligence. Health systems increasingly rely on tissue-based biomarkers such as HER2, PD-L1, ER/PR, ALK, ROS1, BRAF, EGFR, and mismatch repair status to guide targeted therapy and immunotherapy decisions. This makes tissue diagnostics a strategic priority for diagnostic manufacturers, reference laboratories, hospital networks, cancer centers, and pharmaceutical partners developing biomarker-driven therapies.

Transformative Shifts in the Tissue Diagnostics Landscape

The tissue diagnostics landscape is shifting from conventional microscopy-centric workflows toward integrated, data-rich diagnostic ecosystems. Whole-slide imaging, automated staining platforms, digital pathology networks, and laboratory information system integration are improving turnaround time, traceability, and standardization across high-volume pathology operations. These shifts are especially important as pathology workforces face rising case complexity, increasing demand for subspecialty review, and broader use of tissue-based biomarker panels.

At the same time, oncology treatment pathways are becoming more biomarker dependent. Companion diagnostics and complementary diagnostics are moving tissue testing closer to therapy selection, clinical trial enrollment, and real-world evidence generation. Regulatory oversight is also evolving, including heightened scrutiny of laboratory-developed tests in the United States and stricter performance expectations under Europe's In Vitro Diagnostic Regulation, compelling organizations to prioritize analytical validity, clinical evidence, quality management, and traceable workflow documentation.

Cumulative Impact of Artificial Intelligence on Tissue Diagnostics

Artificial intelligence is becoming a practical enabler in tissue diagnostics by supporting image analysis, case prioritization, quality control, biomarker quantification, and workload optimization. AI-assisted tools can help pathologists identify regions of interest, measure staining intensity, quantify tumor-infiltrating lymphocytes, and improve consistency in tasks that are vulnerable to inter-observer variability. These capabilities are most valuable when validated on diverse datasets and embedded into regulated clinical workflows.

The cumulative impact of AI is expected to be operational as much as diagnostic. Digital pathology paired with AI can reduce manual review burden, support remote consultation, strengthen auditability, and accelerate multidisciplinary oncology decision-making. However, adoption depends on evidence-backed validation, interoperability with scanners and laboratory systems, cybersecurity controls, bias monitoring, and clear governance that keeps the pathologist central to final diagnosis.

Key Regional Insights Across the Tissue Diagnostics Landscape

North America remains a leading region for tissue diagnostics due to advanced oncology infrastructure, high adoption of companion diagnostics, strong reimbursement pathways for clinically validated tests, and a large CLIA-certified laboratory base. The United States is particularly influential because of its large cancer testing volume, established pathology networks, and ongoing FDA activity around in vitro diagnostics and laboratory-developed tests. Canada continues to advance digital pathology adoption through provincial health systems, academic hospitals, and cancer care networks.

Europe is defined by strong public health systems, academic pathology expertise, and increasing compliance requirements under the In Vitro Diagnostic Regulation. Germany, France, Italy, Spain, and the United Kingdom are investing in molecular pathology, cancer screening programs, and digital pathology modernization to improve consistency in oncology diagnostics. Asia-Pacific is a rapidly changing opportunity zone, supported by expanding cancer incidence, rising healthcare investment, and large-scale diagnostic capacity building in China, India, Japan, South Korea, Australia, and ASEAN markets.

Latin America is gaining momentum as Brazil and Mexico expand oncology access and reference laboratory capacity, although reimbursement variability, uneven access to molecular testing, and infrastructure gaps remain important constraints. The Middle East is advancing through hospital modernization, medical tourism, and national cancer control strategies, particularly in Gulf countries. Africa represents a long-term access and capacity-building opportunity, where pathology workforce shortages, specimen logistics, and affordability remain critical barriers, while international cancer initiatives and public-private partnerships are gradually improving diagnostic reach.

Key Group Insights Influencing Tissue Diagnostics Demand

The European Union is a central force in tissue diagnostics because harmonized regulatory expectations under the IVDR are reshaping clinical evidence, post-market surveillance, performance evaluation, and quality requirements for diagnostic manufacturers and laboratories. G7 markets collectively drive premium adoption of automated staining, digital pathology, AI-enabled image analysis, and companion diagnostics due to mature oncology systems, established reimbursement structures, and higher healthcare spending.

BRICS countries represent scale-driven demand, led by China and India's expanding cancer burden, Brazil's reference laboratory networks, Russia's domestic oncology needs, and South Africa's role as a regional diagnostic hub. ASEAN markets are increasingly important as Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and Singapore expand hospital capacity, cancer screening programs, and access to immunohistochemistry, though adoption levels differ widely by reimbursement, workforce availability, and laboratory infrastructure.

The GCC is emerging as a high-investment setting for advanced pathology platforms, supported by healthcare diversification strategies, tertiary care expansion, and demand for localized oncology services. NATO countries overlap significantly with high-income diagnostic markets and are relevant for supply chain resilience, cybersecurity standards, and cross-border digital health collaboration, particularly as pathology data, laboratory networks, and AI systems become more connected.

Key Country Insights for Tissue Diagnostics Growth

The United States leads tissue diagnostics adoption through advanced cancer centers, high companion diagnostic utilization, broad immunohistochemistry use, and a large base of independent and hospital-based laboratories. Canada benefits from coordinated cancer care systems and provincial laboratory networks, while Mexico is expanding access through private providers, reference laboratories, and oncology service development. Brazil is Latin America's most significant tissue diagnostics hub, supported by large testing volumes and growing demand for immunohistochemistry and molecular pathology.

In Europe, the United Kingdom is accelerating digital pathology through National Health Service modernization initiatives, while Germany remains a major center for high-quality pathology infrastructure, oncology innovation, and laboratory automation. France, Italy, and Spain continue to strengthen biomarker testing access, cancer screening, and standardized pathology workflows. Russia has substantial domestic demand for oncology diagnostics, but market access, supply chain constraints, and geopolitical factors influence technology availability and procurement patterns.

China is rapidly scaling tissue diagnostics capacity as cancer care expands across public hospitals, regional medical centers, and pathology networks. India is a high-demand market driven by cancer incidence, private laboratory networks, and improving access to immunohistochemistry and molecular testing. Japan and South Korea are mature innovation markets with strong precision oncology adoption, advanced hospital systems, and established pathology expertise, while Australia combines high-quality cancer registries, accredited pathology services, and growing digital pathology implementation.

Actionable Recommendations for Tissue Diagnostics Leaders

Industry leaders should prioritize clinically validated, workflow-integrated tissue diagnostics solutions that reduce turnaround time, improve reproducibility, and support biomarker-guided oncology care. Investment should focus on automated staining, standardized pre-analytics, digital pathology interoperability, AI tools with transparent validation, and scalable data infrastructure that integrates with laboratory information systems and electronic health records.

Organizations should also strengthen regulatory readiness by aligning product development and laboratory services with FDA, CLIA, CAP, ISO, and IVDR expectations where applicable. Partnerships with cancer centers, pharmaceutical developers, and reference laboratories can accelerate companion diagnostic development and evidence generation. In emerging markets, success will depend on affordability, service support, training, reagent reliability, quality assurance, and flexible deployment models that match local pathology capacity.

Research Methodology for Tissue Diagnostics Analysis

This executive summary is built on secondary research, regulatory intelligence, and analysis of publicly available information from authoritative sources, including global cancer statistics, national health agencies, pathology professional organizations, regulatory bodies, peer-reviewed literature, and public disclosures. The research approach emphasizes verified drivers such as cancer incidence, precision medicine adoption, diagnostic workflow modernization, biomarker testing demand, and regulatory change.

Insights were synthesized by comparing regional healthcare infrastructure, reimbursement environments, technology adoption patterns, pathology workforce dynamics, and clinical demand for tissue-based biomarker testing. The methodology avoids unsupported projections and focuses on evidence-backed trends relevant to manufacturers, laboratories, healthcare providers, investors, and strategic decision-makers in the tissue diagnostics ecosystem.

Conclusion: Tissue Diagnostics in Precision Oncology

Tissue diagnostics is moving from a procedural laboratory function to a strategic pillar of precision oncology. Rising cancer incidence, expanding biomarker-driven treatment, and growing demand for faster pathology workflows are increasing the importance of reliable tissue testing across health systems. Digital pathology and AI are not replacing pathologists; they are creating tools that can improve efficiency, consistency, and access when supported by strong validation and governance.

Organizations that combine scientific credibility, regulatory discipline, interoperable technology, and regional market understanding will be best positioned to lead. The strongest opportunities will emerge where tissue diagnostics platforms connect accurate morphology, validated biomarkers, digital workflow, and actionable clinical decision support into a unified oncology diagnostics strategy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Tissue Diagnostics Market, by Product Type

  • 7.1. Instruments
    • 7.1.1. Analyzers & Scanners
    • 7.1.2. Microscopes
  • 7.2. Reagents & Kits
    • 7.2.1. Enzymes & Buffers
    • 7.2.2. Staining Reagents
  • 7.3. Services
    • 7.3.1. Contract Research
    • 7.3.2. Custom Assay Development

8. Tissue Diagnostics Market, by Technology

  • 8.1. Flow Cytometry
    • 8.1.1. Automated Cytometers
    • 8.1.2. Benchtop Cytometers
  • 8.2. Immunohistochemistry
    • 8.2.1. Chromogenic
    • 8.2.2. Fluorescent
  • 8.3. In Situ Hybridization
    • 8.3.1. Cish
    • 8.3.2. Fish
  • 8.4. Microarray & Sequencing
    • 8.4.1. Dna Microarray
    • 8.4.2. Next-Generation Sequencing

9. Tissue Diagnostics Market, by Workflow Stage

  • 9.1. Pre-Analytical
  • 9.2. Analytical
  • 9.3. Post-Analytical

10. Tissue Diagnostics Market, by Application

  • 10.1. Cell Imaging & Analysis
    • 10.1.1. Digital Image Analysis
    • 10.1.2. Fluorescence Microscopy
  • 10.2. Companion Diagnostics
    • 10.2.1. Targeted Therapy Selection
    • 10.2.2. Treatment Efficacy Monitoring
  • 10.3. Infectious Disease
    • 10.3.1. Bacterial Pathogen Detection
    • 10.3.2. Viral Pathogen Detection
  • 10.4. Tumor Profiling
    • 10.4.1. Gene Expression Analysis
    • 10.4.2. Mutation Detection

11. Tissue Diagnostics Market, by End User

  • 11.1. Hospitals & Diagnostic Laboratories
    • 11.1.1. Academic Hospitals
    • 11.1.2. Community Labs
  • 11.2. Pharmaceutical Companies
  • 11.3. Research Institutes
    • 11.3.1. Government Labs
    • 11.3.2. Private Research

12. Tissue Diagnostics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Tissue Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Tissue Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Abcam plc
  • 16.3. Agilent Technologies, Inc.
  • 16.4. Akoya Biosciences, Inc.
  • 16.5. Becton, Dickinson and Company
  • 16.6. Bio-Rad Laboratories, Inc.
  • 16.7. BioGenex Laboratories, Inc.
  • 16.8. bioMerieux SA
  • 16.9. Cell Signaling Technology, Inc.
  • 16.10. Charles River Laboratories International, Inc.
  • 16.11. Danaher Corporation
  • 16.12. F. Hoffmann-La Roche Ltd
  • 16.13. GE HealthCare Technologies Inc.
  • 16.14. Histoline Laboratories S.r.l.
  • 16.15. Hologic, Inc.
  • 16.16. Illumina, Inc.
  • 16.17. Medite Medical GmbH
  • 16.18. Merck KGaA
  • 16.19. PerkinElmer, Inc.
  • 16.20. QIAGEN N.V.
  • 16.21. Quest Diagnostics Incorporated
  • 16.22. Randox Laboratories Ltd
  • 16.23. Sakura Finetek Japan Co., Ltd.
  • 16.24. Siemens Healthineers AG
  • 16.25. SLEE medical GmbH
  • 16.26. Sysmex Corporation
  • 16.27. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TISSUE DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL TISSUE DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL TISSUE DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL TISSUE DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL TISSUE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL TISSUE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANALYZERS & SCANNERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANALYZERS & SCANNERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANALYZERS & SCANNERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MICROSCOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MICROSCOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MICROSCOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENZYMES & BUFFERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENZYMES & BUFFERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENZYMES & BUFFERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STAINING REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STAINING REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STAINING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONTRACT RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTRACT RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONTRACT RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CUSTOM ASSAY DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CUSTOM ASSAY DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CUSTOM ASSAY DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOMATED CYTOMETERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOMATED CYTOMETERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOMATED CYTOMETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BENCHTOP CYTOMETERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BENCHTOP CYTOMETERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BENCHTOP CYTOMETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHROMOGENIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHROMOGENIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHROMOGENIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FLUORESCENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FLUORESCENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FLUORESCENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CISH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CISH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CISH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FISH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FISH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FISH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MICROARRAY & SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MICROARRAY & SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MICROARRAY & SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA MICROARRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DNA MICROARRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA MICROARRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PRE-ANALYTICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRE-ANALYTICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PRE-ANALYTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANALYTICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANALYTICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANALYTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POST-ANALYTICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POST-ANALYTICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POST-ANALYTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL IMAGING & ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL IMAGING & ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL IMAGING & ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIGITAL IMAGE ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIGITAL IMAGE ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIGITAL IMAGE ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FLUORESCENCE MICROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL FLUORESCENCE MICROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL FLUORESCENCE MICROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TARGETED THERAPY SELECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TARGETED THERAPY SELECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TARGETED THERAPY SELECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TREATMENT EFFICACY MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TREATMENT EFFICACY MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TREATMENT EFFICACY MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BACTERIAL PATHOGEN DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BACTERIAL PATHOGEN DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BACTERIAL PATHOGEN DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VIRAL PATHOGEN DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VIRAL PATHOGEN DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VIRAL PATHOGEN DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TUMOR PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENE EXPRESSION ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE EXPRESSION ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE EXPRESSION ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MUTATION DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MUTATION DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MUTATION DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITALS & DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITALS & DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITALS & DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ACADEMIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACADEMIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ACADEMIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMMUNITY LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COMMUNITY LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMMUNITY LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL GOVERNMENT LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GOVERNMENT LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GOVERNMENT LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PRIVATE RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PRIVATE RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PRIVATE RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY MICROARRAY & SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY CELL IMAGING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY TUMOR PROFILING, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY MICROARRAY & SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY CELL IMAGING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY TUMOR PROFILING, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY MICROARRAY & SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY CELL IMAGING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY TUMOR PROFILING, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA TISSUE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY MICROARRAY & SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY CELL IMAGING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY TUMOR PROFILING, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE TISSUE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY MICROARRAY & SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY CELL IMAGING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY TUMOR PROFILING, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST TISSUE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY MICROARRAY & SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY CELL IMAGING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY TUMOR PROFILING, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY MICROARRAY & SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY CELL IMAGING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY TUMOR PROFILING, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN TISSUE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 271. GCC TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 275. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 276. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 278. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 279. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 280. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY MICROARRAY & SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 281. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 282. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY CELL IMAGING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 284. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 285. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 286. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY TUMOR PROFILING, 2018-2032 (USD MILLION)
  • TABLE 287. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 289. GCC TISSUE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY MICROARRAY & SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY CELL IMAGING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY TUMOR PROFILING, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION TISSUE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY MICROARRAY & SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY CELL IMAGING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY TUMOR PROFILING, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS TISSUE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 328. G7 TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 329. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 331. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 332. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 333. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 334. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 335. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 336. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 337. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY MICROARRAY & SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 338. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 339. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 340. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY CELL IMAGING & ANALYSIS, 2018-2032 (USD MILLION)
  • TABLE 341. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 342. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 343. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY TUMOR PROFILING, 2018-2032 (USD MILLION)
  • TABLE 344. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 345. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 346. G7 TISSUE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 347. NATO TISSUE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 348. NATO TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. NATO TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 350. NATO TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 351. NATO TISSUE DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 352. NATO TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 353. NATO TISSUE DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 354. NATO TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 355. NATO TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, 2018-2032 (USD MILLION)
  • TABLE 356. NATO TISSUE DIAGNOSTICS MARKET SIZE, BY MICROARRAY & SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 357. NATO TISSUE DIAGNOSTICS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 358. NATO TISSUE